Forum Archive Index - September 2000

["Steve Moxham" <stevemox@e3.net.nz>]

Hi John,

 

I've just received the report and its 24 pages long. However I'll summarise some of the main points below for those who are interested. If you want a copy I suggest you contact Tom Bliss at Forsyth Barr: tom.bliss@forbar.co.nz He believes that Blis is probably the better buy in comparison to A2.

You could also contact David Parker directly at A2/Blis with any questions. david.parker@a2corporation.co.nz

 

• A2 holds a worldwide exclusive licence to use patent rights and exploit the commercial opportunities from discovering the link between beta casein A1 and coronary heart disease.
• Milk contains two variants of the beta casein protein present in milk: A1 and A2.
• Some cows produce only the A1 variant, some only A2, and some both.
• There is a clear correlation between beta casein A1 consumption and coronary heart disease based on a theory borne out by statistical studies.
• In contrast there is no strong correlation between coronary heart disease and the consumption of red meat, or saturated fats.
• The elimination of the A1 variant from fresh cows milk products could save millions of lives worldwide.
• The discovery is an important key to other respiratory ailments such as asthma and lung cancer, and to other ailments like psoriasis, duodenal ulcers and chronic disorders of the immune system.
• The company believes that worldwide production of milk will shift to cows producing the A2 beta casein variant.
• Together with Genesis Research and Development they have developed a new DNA screening test to test for A1 producing cows.
• A2 has trademarks in Australia, New Zealand, and the USA for "A2 True" milk.
• A2 has already negotiated a sub licence of its technologies to an Australian milk producer and intends promoting its technologies in countries around the world where patents have been sought.